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Abstract
We performed a prospective study of 501 patients, regardless of symptoms, admitted to the hospital, to estimate the predictive value of a
negative nasopharyngeal swab for severe acute respiratory coronavirus virus 2 (SARS-CoV-2). At a positivity rate of 10.2%, the estimated
negative predictive value (NPV) was 97.2% and the NPV rose as prevalence decreased during the study.
(Received 9 September 2020; accepted 2 December 2020)

Establishing a diagnosis of coronavirus disease 2019 (COVID-19)
is based on reverse-transcriptase polymerase chain reaction (RTPCR) testing for severe acute respiratory coronavirus virus 2
(SARS-CoV-2) from a sample obtained using a nasopharyngeal
swab (NP swab).1 False-negative results occur in 27%–37% of these
samples.2,3
False-negative results occur when the laboratory platform does
not detect SARS-CoV-2 RNA in samples confirmed to contain the
virus.2,3,5 But a false-negative result also occurs when insufficient
viral RNA is present on the NP swab.5,6 This insufficiency is related
to the operator performance of the swab and the cooperation of the
patient undergoing testing.
The likelihood that a negative NP swab reflects the absence of
SARS-CoV-2 infection (ie, negative predictive value, NPV) is
related to illness prevalence in the community. The NPV has
not been prospectively derived to date, and having a more complete understanding of this dynamic is critical for clinical decision
making as testing strategies evolve during the pandemic.
The primary objective of this study was to estimate the NPV for
an NP swab. A secondary aim was to estimate the change in NPV as
prevalence changed. Our protocol was based upon prospectively
performing 2 NP swabs on patients admitted to the hospital
through the emergency department and randomly assigning one
swab as the index sample.
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Methods
The study was approved by the institutional review boards of the
Northwell Health System and the Feinstein Institute with a waiver
of informed consent. The study was performed at North
Shore University Hospital in Manhasset, New York, a 760-bed
tertiary-care hospital that is part of the Northwell Health System.
From April 20 onward, all patients admitted to the hospital
from the emergency department, regardless of symptoms, underwent a single NP swab for SARS-CoV-2 testing. Data collection for
this study occurred from May 6 through June 18, 2020. In total, 501
patients were included. Patients were included consecutively over
several time points during the period, but breaks in inclusion
occurred because of concerns about supply (ie, swabs and viral
media) and laboratory capacity. The NP swabbing procedures were
performed by either emergency department physicians, advanced
care providers, or nurses.
Two NP swabs were collected at the same sitting from patients
included in this study, and the operator chose which nostril to
swab. After the swabbing procedure, each swab was placed in a separate tube of viral media and was sent for testing at the central
Northwell Health Laboratories.7 All 1,002 samples in this study
were analyzed on the same platform, which had been previously
validated and reported using clinical samples (Hologic Panther
Fusion, Marlborough, MA).8
Using a random number generator, 1 of the 2 samples from
each patient was designated as the index swab. If the result of
the index swab was positive, the patient was considered positive
for SARS-CoV-2. If the index swab was negative, then the result
of the second NP swab was revealed. If the second NP swab was
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Table 1. Viral Detection, Negative Predictive Value (NPV) and Positivity Rate for Index and Second Swabs by Time Interval and Total
Index Swab Result

Second Swab Result

Period 1, No.

Period 2, No.

Period 3, No.

Period 4, No.

Total, No.

Neg

Neg

202

120

N/A

128

450

Neg

Pos

8

4

N/A

1

13

Pos

Neg

11

5

N/A

2

18

Pos

Pos

14

3

N/A

3

20

Estimated NPV, %

96.2

96.8

N/A

99.2

97.2

Estimated % positivity

14.0

9.1

N/A

4.5

10.2

Note. Neg, negative; pos, positive.

Fig. 1. Positivity rates of the study population
and the overall health system. , Calculated
% Positivity Rate in Study Population; , %
Positivity Rate in Northwell Health System
(Emergency Dept. and Hospitalized Patients).

positive, the negative result on the index NP swab was declared a
false negative.
A patient was considered to have COVID-19 if at least 1 of the 2
NP swabs was positive (true positives plus false negatives). We calculated the positivity rate as a percentage, which is considered a
reflection of prevalence.
The NPV was computed as follows: 1 − (the number of false
negative results divided by the number of negative index swab
results). The exact binomial 95% confidence intervals were also
computed.
To account for changing NPV rates over time, this 44-day interval was divided into equal consecutive periods of 11 days each. No
dual swabs were collected during period 3 because availability of
testing materials was reduced at our hospital during this period
and only 1 swab per patient could be allocated. The calculated positivity rate for each period was compared to the actual system-wide
Northwell Health System positivity rate among patients evaluated
in the emergency department and the hospital for the same period.
Results
For the May 6–June 18 study period, 501 study patients were tested
using 1,002 swabs. Of the 501 study patients, 51 (10.2%) had a positive result on either of the 2 NP swabs. Moreover, 38 index swabs
were positive (7.6%; 95% CI, 5.4%–10.3%). Of the 463 negative
index NP swabs, 13 had a corresponding positive result on the second NP swab (ie, a false-negative result), yielding an index swab
NPV of [1 − (13/463)] or 97.2% (95% CI, 95.69%–98.50%)
(Table 1).
Over the 4 periods, the estimated NPVs were 96.2% (95% CI,
92.6%–98.30%) for period 1, 96.8% (95% CI, 92.0%–99.10%)

for period 2, not available for period 3, and 99.2% (95% CI,
95.8%–99.9%) for period 4. These findings indicate an upward
trend in NPV, as would be expected by the decreasing prevalence of COVID-19 across the study period. The corresponding
positivity rates were 14.0% for period 1, 9.1% for period 2, not
applicable for period 3, and 4.5% for period 4. The SARS-CoV-2
positivity rate for the health system emergency department and
hospitalized patients during these 4 intervals was 13.9% (1,473
positives of 10,597 patients) for period 1, 8.9% (1,056 of 11,872
patients) for period 2, 5.7% (726 of 12,769 patients) for period 3,
and 4.1% (519 of 12,768 patients) for period 4 (Fig. 1). The calculated positivity rate for the three 11-day intervals during
which 2 swabs could be performed in this study, correlates significantly with the actual positive test rate for our health system
(R2 > 0.99; P < .01).
Discussion
A major strength of our study was the method of prospectively performing dual NP swabs on all patients regardless of symptoms. We
demonstrated that false-negative test results occur and that the
estimated NPV correlates with prevalence.
In our study, in which both NP swabs were performed in the
same sitting, several factors that should have led to both swabs
yielding the same outcome: (1) The quantity of virus in the nasopharynx would be expected to be the same, (2) specimens were
processed in the same manner, and (3) the testing platform for
each specimen was the same. Therefore, we believe that a major
influence for false-negative results for the index samples is the
quality of the sample, which is affected by the technique of the
operator and the cooperation of the patient.
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This study has several limitations. It was initiated after the peak
of SARS-CoV-2 test prevalence positivity rates in the New York
region. During the entire period that our study considered, just
>10% of patients had a positive result, and prevalence during
the overall study period. However, our findings remain applicable
because many population prevalence rates being encountered now
in the United States are 10% or lower.9
Although predictive value is influenced by illness prevalence, it
is also affected by clinical signs and symptoms. These data were not
included in this study. However, many centers, like ours, are currently screening all patients admitted to their hospitals.
Additionally, as testing evolves and expands in the community,
most patients tested will not have symptoms of COVID-19, but will
be tested as part of broader screening strategies. At the prevalence
rates observed in our study, we believe that our findings can be
applied.
In summary, we performed a study of 501 patients to prospectively estimate the predictive value of negative NP swabs during
periods of changing prevalence of infection. The overall NPV of
>97% occurred during an period in which the estimated positivity
rate was 10%, and the study cohort positivity rates matched the
overall positivity rates encountered by our health system during
the same periods.
False-negative results and NPV have yet to be estimated by a
prospective design like we have performed. We believe that comprehensively understanding test attributes is critical as the pandemic evolves. Our study design demonstrates that sample
quality influences the occurrence of false-negative results and that
opportunities exist to optimize sampling quality.
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